(fifthQuint)Study to Compare PT007 to Placebo MDI and Open-Label Proventil HFA in Adult and Adolescent Subjects With Asthma.

 This is a 5-period crossover study.

 Each Treatment Period is 1 day.

 Subjects will receive a single dose of randomized study drug at each of the 5 Treatment Visits (Visits 2, 3, 4, 5, and 6), with a 3- to 7-day Washout Period between Treatment Visits.

.

 Study to Compare PT007 to Placebo MDI and Open-Label Proventil HFA in Adult and Adolescent Subjects With Asthma@highlight

This is a randomized, double-blind, single-dose, placebo-controlled, 5-period, 5-treatment, crossover, multi-center study to assess the bronchodilatory effect and safety of 2 dose levels of Albuterol Sulfate Pressurized Inhalation Suspension (hereafter referred to as AS MDI), 90 1/2g and 180 1/2g, compared with placebo for AS MDI (hereafter referred to as Placebo MDI) and open-label Proventil(R) hydrofluoroalkane (HFA; hereafter referred to as Proventil) 90 1/2g and 180 1/2g in adult and adolescent subjects with mild to moderate asthma.

 This study design utilizes 10 treatment sequences.

